Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Yazici

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Clinical and Experimental Rheumatology|November 4, 2010
Long-term safety of methotrexate in the treatment of rheumatoid arthritisY Yazici
Clinical and Experimental Rheumatology|November 9, 2005
A database in private practice: the Brooklyn Outcomes of Arthritis Rheumatology Database (BOARD)Y Yazici
Annals of the Rheumatic Diseases|July 13, 2006
A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitorsY Yazici, H Yazici
Clinical and Experimental Rheumatology|June 27, 2008
Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritisY Yazici, H Yazici
Clinical Cornerstone|February 26, 2000
A diagnostic approach to musculoskeletal painY Yazici, A Gibofsky
Rheumatic Diseases Clinics of North America|September 16, 2000
Elderly-onset rheumatoid arthritisY Yazici, S A Paget
Clinical and Experimental Rheumatology|November 9, 2005
Laboratory monitoring of biologic therapiesJ J Cush, Y Yazici
Inquiry : a Journal of Medical Care Organization, Provision and Financing|July 13, 2000
Medicaid expansions and the crowding out of private health insurance among childrenE Y Yazici, R Kaestner
Current Opinion in Rheumatology|November 25, 2000
The association of malignancy with myositisY Yazici, L J Kagen
Clinical and Experimental Rheumatology|July 17, 2009
Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experienceE K Schimmel, Y Yazici
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Clinical and Experimental Rheumatology|November 4, 2010
Long-term safety of methotrexate in the treatment of rheumatoid arthritisY Yazici
Clinical and Experimental Rheumatology|November 9, 2005
A database in private practice: the Brooklyn Outcomes of Arthritis Rheumatology Database (BOARD)Y Yazici
Annals of the Rheumatic Diseases|July 13, 2006
A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitorsY Yazici, H Yazici
Clinical and Experimental Rheumatology|June 27, 2008
Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritisY Yazici, H Yazici
Clinical Cornerstone|February 26, 2000
A diagnostic approach to musculoskeletal painY Yazici, A Gibofsky
Rheumatic Diseases Clinics of North America|September 16, 2000
Elderly-onset rheumatoid arthritisY Yazici, S A Paget
Clinical and Experimental Rheumatology|November 9, 2005
Laboratory monitoring of biologic therapiesJ J Cush, Y Yazici
Inquiry : a Journal of Medical Care Organization, Provision and Financing|July 13, 2000
Medicaid expansions and the crowding out of private health insurance among childrenE Y Yazici, R Kaestner
Current Opinion in Rheumatology|November 25, 2000
The association of malignancy with myositisY Yazici, L J Kagen
Clinical and Experimental Rheumatology|July 17, 2009
Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experienceE K Schimmel, Y Yazici
Pageof 5